

**Morning Keynote Speaker: Christine E. Vannais, COO,  
FUJIFILM Diosynth Biotechnologies**



**Innovations in BioManufacturing, a CDMO perspective**

This year marks the 40th year of the approval of the first FDA approve biotechnology drug. Our industry has evolved tremendously and we have seen incredible changes to make life impacting medicines available.

We have seen an evolution and expansion in the modalities that are going through the drug development life cycle. Biomanufacturing needs to be ready with the required infrastructure, innovation, flexibility and expertise to deliver these treatments.

CDMOs, such as FUJIFILM Diosynth Biotechnologies, are implementing innovations that will drive the future of Biomanufacturing. Innovation in the CDMO spaces, can be different than innovation from discovery and molecule ownership and will bring different value.

**About the speaker**

**Christine E. Vannais** – Chief Operating Officer at FUJIFILM Diosynth Biotechnologies at the RTP site in North Carolina, since April 2020.

Christine joined FUJIFILM Diosynth Biotechnologies family in 2012 and she has led the North Carolina Manufacturing Operations team since 2014 as part of the Site Leadership Team. In this role she has been responsible for the site's 24/7 manufacturing operations, which include cGMP production in both microbial and mammalian systems, for clinical and commercial drug substance delivery. In this role, Mrs. Vannais is responsible for the site quality compliance and delivery, with the support of the Quality Organization.

Mrs. Vannais brings over twenty years of experience working in a variety of industries including contract biopharmaceutical development and manufacturing, USDA biological vaccine manufacturing and research, FDA and EU small molecule manufacturing, primary and secondary packaging operations, API potent compound manufacturing, Department of Defense sites, among others. She has a bachelor's degree in Environmental Health from Colorado State University.